USClinicalTrials.govClinical trialPhase 2Active, not recruiting
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
Official record
- Identifier
NCT05329766- Recruiting locations
countries
United StatesCanadaChileFranceSerbiaSouth Korea- Interventions studied
- DomvanalimabQuemliclustatZimberelimabFluorouracilLeucovorinOxaliplatin
- Lead sponsor
- Arcus Biosciences, Inc.
- Target enrolment
- 332 participants
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Status
- Active, not recruiting
- First posted
- Apr 15, 2022
- Last updated on the registry
- Sep 29, 2026
- Age
- 18 Years
- Sex
- ALL
- Study contact
- No public contact is listed on the official record.
- Eligibility criteria
Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.
Key Inclusion Criteria: * Participants with histologically confirmed diagnosis of locally advanced unresectable or metastatic gastric, GEJ, or esophageal adenocarcinoma with life expectancy ≥3 months as assessed by the Investigator * Eastern cooperative oncology group (ECOG) Performance Score of 0-1 * At least one measurable target lesion per RECIST v1.1. * Adequate organ and marrow function * Able to provide an archival tumor sample that is representative of the cancer under investigation and suitable for central PD-L1 testing Key Exclusion Criteria: * Participants with underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of investigational products hazardous * Only for Cohort A: Known Human Epidermal Growth Factor Receptor 2 (HER-2) positive tumor * Known untreated, symptomatic, or actively progressing central nervous system (brain) metastases. Participants with leptomeningeal metastases are excluded from enrollment. * Discontinued use of prior immune checkpoint therapy due to immune related adverse events; received prior treatment with an anti-TIGIT monoclonal antibody. * History of trauma or major surgery within 28 days prior to enrollment. Note: Other protocol defined Inclusion/Exclusion criteria may apply.
- Indexed under
- Gastric Cancer